News &
Media
-
Australia’s top 20 cannabis companies
View More: Australia’s top 20 cannabis companiesA report from FreshLeaf Analytics forecasts Australian medicinal cannabis sales of $423 million for 2022, up from an estimated $230 million in 2021. As prices for practically everything rose last year, medicinal cannabis prices went down on average, opening up more budgets to treatment.
-
Neurotech International (ASX:NTI) appoints Alexandra Andrews as CEO
View More: Neurotech International (ASX:NTI) appoints Alexandra Andrews as CEODr Andrews has experience in corporate development, investor engagement, product development and commercialisation, clinical trials and regulatory environments.
She has a Doctor of Philosophy in Neuroscience from the University of Western Australia.
-
Neurotech International Phase I/II Autism Results Due this Quarter
View More: Neurotech International Phase I/II Autism Results Due this QuarterIn July last year Neurotech International (NTI: $0.05) acquired a license from Dolce CannGroup for access to specific proprietary strains of cannabis for the potential treatment of various neurological conditions.
-
Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans
View More: Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans -
From Backstreet to Highstreet: How Cannabis Has Entered the Mainstream
View More: From Backstreet to Highstreet: How Cannabis Has Entered the MainstreamExplore the $31.96 billion global cannabis market that is disrupting the healthcare and pharmaceutical industries.
-
Australia’s Neurotech Inks Cannabis Cultivation Partnership
View More: Australia’s Neurotech Inks Cannabis Cultivation PartnershipNeurotech International Limited (ASX:NTI) has established a strategic medical cannabis cultivation partnership with CannaPacific Limited.
-
Neurotech just started world’s first THC-less cannabis study in autistic children
View More: Neurotech just started world’s first THC-less cannabis study in autistic childrenThe Phase I/II clinical trial announced today is a groundbreaking study where medicinal cannabis containing little to no THC is being tested on autistic children.
-
Neurotech embarks on ground-breaking ASD trials
View More: Neurotech embarks on ground-breaking ASD trialsNeurotech International Limited (ASX:NTI) has commenced a Phase I/II open label clinical study in 20 children aged between 5-17 years with Autism Spectrum Disorder (ASD).
-
Neurotech International (ASX:NTI) secures option to Dolce Cann Global’s cannabis strains
View More: Neurotech International (ASX:NTI) secures option to Dolce Cann Global’s cannabis strainsNeurotech International (NTI) has secured an option to acquire an exclusive worldwide licence to use cannabis strains from Dolce Cann Global.
The proprietary cannabis strains will be medicinally used to treat neurological disorders such as autism, epilepsy and ADHD.